Data gathered: May 29
Alternative Data for Evolus
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 21 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 51,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | 40 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| App Downloads | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 9 | Sign up | Sign up | Sign up |
| Facebook Followers | 7,608 | Sign up | Sign up | Sign up |
| Instagram Followers | 54,656 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,846 | Sign up | Sign up | Sign up |
| Twitter Followers | 705 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 91 | Sign up | Sign up | Sign up |
| Linkedin Employees | 402 | Sign up | Sign up | Sign up |
About Evolus
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.
| Price | $9.30 |
| Target Price | Sign up |
| Volume | 2,380,000 |
| Market Cap | $633M |
| Year Range | $9.3 - $17.45 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Drug Manufacturers |
In the news
 |
Evolus Announces Departure of its Chief Financial OfficerMay 27 - Yahoo |
 |
BNP Paribas Financial Markets Has $400,000 Position in Evolus, Inc. (NASDAQ:EOLS)May 26 - ETF Daily News |
|
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid GelsMay 21 - Yahoo |
Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid GelsMay 21 - Finnhub |
|
|
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16 - Yahoo |
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 16 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 69M | 22M | 47M | -19M | 0 | -0.170 |
| Q4 '24 | 79M | 29M | 50M | -6.8M | -3.1M | 0.014 |
| Q3 '24 | 61M | 18M | 43M | -19M | -23M | -0.160 |
| Q2 '24 | 67M | 21M | 46M | -11M | -5.2M | -0.040 |
| Q1 '24 | 59M | 19M | 40M | -13M | -6.8M | -0.090 |
Insider Transactions View All
| Beaver Sandra filed to sell 167,089 shares at $10. May 14 '25 |
| Avelar Rui filed to sell 359,082 shares at $9.9. May 14 '25 |
| MOATAZEDI DAVID filed to sell 492,832 shares at $9.9. May 14 '25 |
| MOATAZEDI DAVID filed to sell 508,619 shares at $12.4. March 28 '25 |
| Yamagishi-Dressler Tomoko filed to sell 95,671 shares at $13.3. March 20 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$152.43 0% | 49 |
 |
Eli Lilly and CompanyLLY |
$719.39 0% | 70 |
 |
PfizerPFE |
$23.18 0% | 44 |
 |
AstrazenecaAZN |
$70.38 0% | 51 |
 |
AbbVieABBV |
$183.09 0% | 49 |
Read more about Evolus (EOLS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, app downloads, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Evolus?
The Market Cap of Evolus is $633M.
What is the current stock price of Evolus?
Currently, the price of one share of Evolus stock is $9.30.
How can I analyze the EOLS stock price chart for investment decisions?
The EOLS stock price chart above provides a comprehensive visual representation of Evolus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Evolus shares. Our platform offers an up-to-date EOLS stock price chart, along with technical data analysis and alternative data insights.
Does EOLS offer dividends to its shareholders?
As of our latest update, Evolus (EOLS) does not offer dividends to its shareholders. Investors interested in Evolus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Evolus?
Some of the similar stocks of Evolus are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.